高级检索
当前位置: 首页 > 详情页

The tumor suppressor interferon regulatory factor 8 inhibits beta-catenin signaling in breast cancers, but is frequently silenced by promoter methylation

文献详情

资源类型:
机构: [1]Chongqing Med Univ, Chongqing Key Lab Mol Oncol & Epigenet, Affiliated Hosp 1, Chongqing, Peoples R China; [2]Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China; [3]Chinese Univ Hong Kong, State Key Lab Oncol South China, Sir YK Pao Ctr Canc, Dept Clin Oncol,Canc Epigenet Lab, Shatin, Hong Kong, Peoples R China; [4]Chinese Univ Hong Kong, Li Ka Shine Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [5]CUHK Shenzhen Reaesrch Inst, Shatin, Hong Kong, Peoples R China
出处:
ISSN:

关键词: interferon regulatory factor 8 methylation tumor suppressor breast cancer beta-catenin

摘要:
Interferon (IFN) regulatory factor 8 is encoded by a novel candidate tumor suppressor gene (IRF8), its promotor is frequently methylated in multiple cancers. However, the promoter methylation status, functions and underlying mechanisms of IRF8 in breast cancer remain unclear. We found that IRF8 was downregulated in breast cancer cell lines and primary tumors, compared with normal breast tissues, mainly because of aberrant promoter methylation. However, its expression was not associated with pathological characteristics. Restoration of IRF8 expression suppressed cell proliferation, colony formation, 5-ethynyl-2'-deoxyuridine incorporation, cell migration and invasion, and induced apoptosis and cell cycle arrest in vitro. IRF8 also inhibited xenograft growth in nude mice in vivo. Competition with IRF8 function by IRF8 mutant (K79E) enhanced cell migration and invasion in 4T1 murine cells in vitro. Importantly, IRF8, as both downstream target gene and regulator of IFN-(Upsilon)/STAT1 signaling, inhibited canonical beta-catenin signaling. These findings identify IRF8 as a novel tumor suppressor regulating IFN-(Upsilon)/STAT1 signaling and beta-catenin signaling in breast cancer.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学 3 区 细胞生物学
最新[2023]版:
第一作者:
第一作者机构: [1]Chongqing Med Univ, Chongqing Key Lab Mol Oncol & Epigenet, Affiliated Hosp 1, Chongqing, Peoples R China; [2]Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China;
通讯作者:
通讯机构: [1]Chongqing Med Univ, Chongqing Key Lab Mol Oncol & Epigenet, Affiliated Hosp 1, Chongqing, Peoples R China; [2]Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China; [3]Chinese Univ Hong Kong, State Key Lab Oncol South China, Sir YK Pao Ctr Canc, Dept Clin Oncol,Canc Epigenet Lab, Shatin, Hong Kong, Peoples R China; [4]Chinese Univ Hong Kong, Li Ka Shine Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [5]CUHK Shenzhen Reaesrch Inst, Shatin, Hong Kong, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号